Alaunos Therapeutics Inc Cash Flow-to-Debt Ratio
Alaunos Therapeutics Inc cash flow-to-debt ratio. Alaunos Therapeutics Inc (TCRT) has a Cash Flow-to-Debt Ratio of -0.35x as of June 2026, meaning its operating cash flow of $-300.00K could theoretically repay 0% of its total liabilities ($864.00K) in one year. Check Alaunos Therapeutics Inc (TCRT) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Alaunos Therapeutics Inc (2001–2025)
Cash flow-to-debt ratio of Alaunos Therapeutics Inc from 2001 to 2025. Historical debt coverage capacity for Alaunos Therapeutics Inc across 25 annual periods. Check TCRT total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Alaunos Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2001–2025)
Alaunos Therapeutics Inc cash flow-to-debt ratio by year from 2001 to 2025. Year-by-year debt coverage analysis for Alaunos Therapeutics Inc. For the full cash flow conversion analysis, see how efficiently does Alaunos Therapeutics Inc generate cash.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.53x | $-2.87 Million | $813.00K | ▲ +50.9% |
| 2024 | -7.18x | $-4.97 Million | $692.00K | ▲ +53.4% |
| 2023 | -15.41x | $-30.14 Million | $1.96 Million | ▼ -1290.8% |
| 2022 | -1.11x | $-29.23 Million | $26.38 Million | ▲ +33.6% |
| 2021 | -1.67x | $-61.47 Million | $36.81 Million | ▲ +34.5% |
| 2020 | -2.55x | $-57.01 Million | $22.36 Million | ▲ +12.0% |
| 2019 | -2.90x | $-40.85 Million | $14.10 Million | ▲ +44.4% |
| 2018 | -5.21x | $-49.46 Million | $9.49 Million | ▼ -1830.2% |
| 2017 | -0.27x | $-54.67 Million | $202.41 Million | ▲ +15.0% |
| 2016 | -0.32x | $-58.33 Million | $183.65 Million | ▼ -210633.6% |
| 2015 | 0.00x | $-10.00K | $66.35 Million | ▲ +100.0% |
| 2014 | -3.22x | $-36.65 Million | $11.40 Million | ▼ -20.9% |
| 2013 | -2.66x | $-59.51 Million | $22.37 Million | ▼ -18.0% |
| 2012 | -2.25x | $-78.83 Million | $34.96 Million | ▼ -111.9% |
| 2011 | -1.06x | $-38.84 Million | $36.50 Million | ▼ -67.3% |
| 2010 | -0.64x | $-19.69 Million | $30.97 Million | ▼ -11.9% |
| 2009 | -0.57x | $-12.29 Million | $21.63 Million | ▲ +85.9% |
| 2008 | -4.03x | $-23.52 Million | $5.83 Million | ▼ -18.4% |
| 2007 | -3.41x | $-21.65 Million | $6.36 Million | ▲ +29.6% |
| 2006 | -4.84x | $-14.42 Million | $2.98 Million | ▼ -26.3% |
| 2005 | -3.83x | $-8.78 Million | $2.29 Million | ▼ -1003.4% |
| 2004 | -0.35x | $-7.31K | $21.05K | ▲ +4.2% |
| 2003 | -0.36x | $-9.33K | $25.72K | ▲ +45.0% |
| 2002 | -0.66x | $-11.77K | $17.84K | ▲ +88.0% |
| 2001 | -5.50x | $-30.26K | $5.50K | — |